The use of GM-CSF and peripheral blood stem cells (PBSC) minimises haematological toxicity following a myeloablative course of chemo-radiotherapy.
Gianni
A M
AM
Istituto Nazionale Tumori, Milano, Italy.
Siena
S
S
Bregni
M
M
Bonadonna
G
G
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy; D011832:Radiation Injuries / Q000517:prevention & control*
D000970:Antineoplastic Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor